BioCryst reports third quarter 2026 financial results
The rare disease specialist's quarterly update comes as it works to grow its hereditary angioedema franchise.
Read at Stock Titan →Full coverage · 11 outlets
- Stock Titan · lead
- GlobeNewswireBioCryst Reports Third Quarter 2026 Financial Results
- Yahoo FinanceBioCryst to Report Third Quarter 2026 Financial Results on November 4
- The Manila TimesShoals Technologies Group, Inc. Reports Financial Results for Third Quarter 2026
- scanx.tradeBioCryst Pharmaceuticals Q3FY26 Results: Earnings call set for Nov 4
- Yahoo! Finance CanadaHLF,BSBK,FXNC,IMRX,MRBK,PDYN,GRNT,TPL,FTHM,VSTS,RVSB,GEF-B,SHEN,TMCI,BCRX,NBBK,CION,USCB,JOB,ASTC,ACDC | Stock Prices | Quote Comparison - Yahoo Finance
- ad-hoc-news.deWedbush cuts target for BioCryst stock from USD 20.00 to USD 18.00
- Business WireAstria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
- Yahoo Finance SingaporeShanghai Henlius Biotech, Inc. (2696.HK) stock price, news, quote and history
- TradingViewBCRX Stock Price and Chart - NASDAQ:BCRX
- BusinessinsiderBioCryst Reports Third Quarter 2026 Financial Results